SPRO | Spero Therapeutics, Inc. | [NASD]
Index- P/E- EPS (ttm)-0.90 Insider Own0.80% Shs Outstand52.53M Perf Week-7.33%
Market Cap92.00M Forward P/E- EPS next Y-0.98 Insider Trans-6.43% Shs Float39.69M Perf Month0.00%
Income-26.90M PEG- EPS next Q-0.38 Inst Own38.70% Short Float / Ratio2.46% / 1.73 Perf Quarter19.59%
Sales53.50M P/S1.72 EPS this Y57.50% Inst Trans-5.30% Short Interest0.97M Perf Half Y-7.81%
Book/sh1.23 P/B1.44 EPS next Y18.30% ROA-29.40% Target Price6.33 Perf Year47.50%
Cash/sh- P/C- EPS next 5Y36.90% ROE-51.30% 52W Range0.68 - 3.18 Perf YTD2.31%
Dividend- P/FCF12.27 EPS past 5Y17.40% ROI-60.30% 52W High-44.34% Beta0.89
Dividend %- Quick Ratio4.40 Sales past 5Y93.40% Gross Margin- 52W Low160.26% ATR0.09
Employees41 Current Ratio4.40 Sales Q/Q0.00% Oper. Margin-55.70% RSI (14)47.58 Volatility4.58% 5.28%
OptionableYes Debt/Eq0.00 EPS Q/Q74.90% Profit Margin-50.20% Rel Volume0.55 Prev Close1.77
ShortableYes LT Debt/Eq0.00 EarningsMay 11 AMC Payout- Avg Volume563.24K Price1.77
Recom2.20 SMA20-4.45% SMA505.33% SMA2006.63% Volume308,341 Change0.00%
Date Action Analyst Rating Change Price Target Change
Sep-23-22Upgrade Evercore ISI In-line → Outperform $2 → $8
Oct-01-21Downgrade Oppenheimer Outperform → Perform
Jan-22-21Reiterated H.C. Wainwright Buy $33 → $40
Dec-16-20Initiated Berenberg Buy $47
Sep-29-20Initiated Evercore ISI Outperform
Nov-05-19Reiterated H.C. Wainwright Buy $28 → $35
Sep-09-19Initiated Janney Buy
Feb-09-18Initiated Cantor Fitzgerald Overweight $27
Nov-27-17Initiated Stifel Buy $26
Nov-27-17Initiated Oppenheimer Outperform $30
Nov-27-17Initiated BofA/Merrill Neutral $16
May-18-23 07:09AM
May-16-23 11:36AM
May-12-23 05:30AM
May-11-23 05:35PM
08:05AM Loading…
May-04-23 08:05AM
Apr-28-23 04:05PM
Apr-26-23 08:05AM
Apr-17-23 07:14AM
Apr-14-23 08:05AM
Apr-13-23 06:19AM
Apr-05-23 09:59PM
Apr-01-23 09:07AM
Mar-31-23 04:05PM
Mar-30-23 06:05PM
04:05PM Loading…
Mar-13-23 08:05AM
Mar-06-23 08:05AM
Feb-28-23 04:05PM
Feb-23-23 09:35AM
Feb-22-23 09:35AM
Jan-31-23 04:05PM
Jan-14-23 08:03AM
Dec-22-22 04:05PM
Nov-22-22 08:05AM
Nov-16-22 05:55AM
Nov-14-22 05:25PM
Nov-08-22 08:05AM
08:05AM Loading…
Nov-07-22 08:05AM
Nov-02-22 10:01AM
Oct-19-22 08:05AM
Oct-03-22 08:05AM
Sep-25-22 07:00AM
Sep-23-22 11:02AM
Sep-22-22 11:30AM
Sep-15-22 04:05PM
Sep-07-22 12:37PM
Sep-06-22 10:10AM
Sep-05-22 06:49AM
Aug-25-22 09:55AM
Aug-10-22 05:25PM
Aug-09-22 08:05AM
Jul-06-22 02:30AM
Jun-27-22 04:27PM
May-31-22 07:30AM
May-16-22 05:35PM
May-11-22 08:05AM
May-09-22 08:05AM
May-04-22 09:15AM
May-03-22 05:29PM
Apr-28-22 03:02PM
Apr-21-22 08:05AM
Apr-06-22 05:31PM
Mar-31-22 05:55PM
Mar-29-22 10:39AM
Mar-28-22 06:51PM
Mar-17-22 08:05AM
Feb-16-22 08:05AM
Feb-10-22 10:47AM
Jan-20-22 05:36AM
Jan-19-22 08:05AM
Jan-04-22 11:38AM
Jan-03-22 08:05AM
Dec-28-21 02:38AM
Nov-17-21 08:05AM
Nov-12-21 11:06AM
Nov-10-21 05:45PM
Nov-03-21 08:05AM
Oct-28-21 03:05PM
Oct-12-21 08:05AM
Oct-05-21 07:11AM
Oct-01-21 04:01PM
Sep-30-21 03:00PM
Sep-28-21 12:45PM
Sep-16-21 08:05AM
Sep-07-21 08:05AM
Sep-02-21 08:46AM
Aug-31-21 04:25PM
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, a novel oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Mahadevia AnkitCEO and PresidentFeb 03Sale1.8112,28622,238797,832Feb 06 04:15 PM
Shukla SathChief Financial OfficerFeb 02Sale1.839,50417,372312,517Feb 03 07:41 PM
JOSEPH TAMARA LChief Legal OfficerFeb 02Sale1.863,3946,313324,644Feb 03 07:43 PM
Keutzer TimothyChief Operating OfficerFeb 02Sale1.863,3946,313327,144Feb 03 07:43 PM
Aquilo Capital Management, LLC10% OwnerSep 22Sale2.251,901,7964,279,6123,419,435Sep 26 03:32 PM
Shukla SathChief Financial OfficerAug 29Sale0.896,0175,37856,064Aug 30 05:00 PM